In 2017, the European LeukaemiaNet [2] factored in the significance of mutational events in AML and improved the predictive strategy for response to therapy and survival by adding recently recognised mutations in RUNX1, ASXL1 and BCR‐ABL1 to the known risk contribution delimited by mutations in NPM1, FLT‐ITD, CEBPA and TP53. Here, NPM1 is linked to acute myeloid leukemia.